212 related articles for article (PubMed ID: 31881024)
1. Platelet thrombus formation in eHUS is prevented by anti-MBL2.
Kushak RI; Boyle DC; Rosales IA; Ingelfinger JR; Stahl GL; Ozaki M; Colvin RB; Grabowski EF
PLoS One; 2019; 14(12):e0220483. PubMed ID: 31881024
[TBL] [Abstract][Full Text] [Related]
2. Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury.
Ozaki M; Kang Y; Tan YS; Pavlov VI; Liu B; Boyle DC; Kushak RI; Skjoedt MO; Grabowski EF; Taira Y; Stahl GL
Kidney Int; 2016 Oct; 90(4):774-82. PubMed ID: 27378476
[TBL] [Abstract][Full Text] [Related]
3. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.
Morigi M; Galbusera M; Gastoldi S; Locatelli M; Buelli S; Pezzotta A; Pagani C; Noris M; Gobbi M; Stravalaci M; Rottoli D; Tedesco F; Remuzzi G; Zoja C
J Immunol; 2011 Jul; 187(1):172-80. PubMed ID: 21642543
[TBL] [Abstract][Full Text] [Related]
4. Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome.
Karpman D; Papadopoulou D; Nilsson K; Sjögren AC; Mikaelsson C; Lethagen S
Blood; 2001 May; 97(10):3100-8. PubMed ID: 11342436
[TBL] [Abstract][Full Text] [Related]
5. Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers.
Nolasco LH; Turner NA; Bernardo A; Tao Z; Cleary TG; Dong JF; Moake JL
Blood; 2005 Dec; 106(13):4199-209. PubMed ID: 16131569
[TBL] [Abstract][Full Text] [Related]
6. Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS).
Exeni RA; Fernandez-Brando RJ; Santiago AP; Fiorentino GA; Exeni AM; Ramos MV; Palermo MS
Pediatr Nephrol; 2018 Nov; 33(11):2057-2071. PubMed ID: 29372302
[TBL] [Abstract][Full Text] [Related]
7. Complement contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome.
Karpman D; Tati R
Kidney Int; 2016 Oct; 90(4):726-9. PubMed ID: 27633864
[TBL] [Abstract][Full Text] [Related]
8. Shiga toxin triggers endothelial and podocyte injury: the role of complement activation.
Zoja C; Buelli S; Morigi M
Pediatr Nephrol; 2019 Mar; 34(3):379-388. PubMed ID: 29214442
[TBL] [Abstract][Full Text] [Related]
9. Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice.
Zoja C; Locatelli M; Pagani C; Corna D; Zanchi C; Isermann B; Remuzzi G; Conway EM; Noris M
J Immunol; 2012 Oct; 189(7):3661-8. PubMed ID: 22942429
[TBL] [Abstract][Full Text] [Related]
10. Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome.
Ståhl AL; Sartz L; Nelsson A; Békássy ZD; Karpman D
PLoS One; 2009 Sep; 4(9):e6990. PubMed ID: 19750223
[TBL] [Abstract][Full Text] [Related]
11. Shiga toxin targets the podocyte causing hemolytic uremic syndrome through endothelial complement activation.
Bowen EE; Hurcombe JA; Barrington F; Keir LS; Farmer LK; Wherlock MD; Ortiz-Sandoval CG; Bruno V; Bohorquez-Hernandez A; Diatlov D; Rostam-Shirazi N; Wells S; Stewart M; Teboul L; Lay AC; Butler MJ; Pope RJP; Larkai EMS; Morgan BP; Moppett J; Satchell SC; Welsh GI; Walker PD; Licht C; Saleem MA; Coward RJM
Med; 2023 Nov; 4(11):761-777.e8. PubMed ID: 37863058
[TBL] [Abstract][Full Text] [Related]
12. Response to single and divided doses of Shiga toxin-1 in a primate model of hemolytic uremic syndrome.
Siegler RL; Pysher TJ; Tesh VL; Taylor FB
J Am Soc Nephrol; 2001 Jul; 12(7):1458-1467. PubMed ID: 11423574
[TBL] [Abstract][Full Text] [Related]
13. Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction.
Zoja C; Buelli S; Morigi M
Pediatr Nephrol; 2010 Nov; 25(11):2231-40. PubMed ID: 20424866
[TBL] [Abstract][Full Text] [Related]
14. Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement.
Locatelli M; Buelli S; Pezzotta A; Corna D; Perico L; Tomasoni S; Rottoli D; Rizzo P; Conti D; Thurman JM; Remuzzi G; Zoja C; Morigi M
J Am Soc Nephrol; 2014 Aug; 25(8):1786-98. PubMed ID: 24578132
[TBL] [Abstract][Full Text] [Related]
15. Soluble CD40 Ligand and Oxidative Response Are Reciprocally Stimulated during Shiga Toxin-Associated Hemolytic Uremic Syndrome.
Abrey Recalde MJ; Alvarez RS; Alberto F; Mejias MP; Ramos MV; Fernandez Brando RJ; Bruballa AC; Exeni RA; Alconcher L; Ibarra CA; Amaral MM; Palermo MS
Toxins (Basel); 2017 Oct; 9(11):. PubMed ID: 29068360
[TBL] [Abstract][Full Text] [Related]
16. von Willebrand Factor expression in a Shiga toxin-mediated primate model of hemolytic uremic syndrome.
Pysher TJ; Siegler RL; Tesh VL; Taylor FB
Pediatr Dev Pathol; 2002; 5(5):472-9. PubMed ID: 12196894
[TBL] [Abstract][Full Text] [Related]
17. Treatment of typical (enteropathic) hemolytic uremic syndrome.
Bitzan M; Schaefer F; Reymond D
Semin Thromb Hemost; 2010 Sep; 36(6):594-610. PubMed ID: 20865636
[TBL] [Abstract][Full Text] [Related]
18. Shiga Toxin Mediated Neurologic Changes in Murine Model of Disease.
Pradhan S; Pellino C; MacMaster K; Coyle D; Weiss AA
Front Cell Infect Microbiol; 2016; 6():114. PubMed ID: 27747196
[TBL] [Abstract][Full Text] [Related]
19. Fractalkine and CX3CR1 mediate leukocyte capture by endothelium in response to Shiga toxin.
Zanchi C; Zoja C; Morigi M; Valsecchi F; Liu XY; Rottoli D; Locatelli M; Buelli S; Pezzotta A; Mapelli P; Geelen J; Remuzzi G; Hawiger J
J Immunol; 2008 Jul; 181(2):1460-9. PubMed ID: 18606701
[TBL] [Abstract][Full Text] [Related]
20. Shiga toxin (Stx)1B and Stx2B induce von Willebrand factor secretion from human umbilical vein endothelial cells through different signaling pathways.
Liu F; Huang J; Sadler JE
Blood; 2011 Sep; 118(12):3392-8. PubMed ID: 21816831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
